Markets: 2026-09-08 Close

A sourced recap of the previous completed U.S. trading session. Closing moves are not real-time quotes.

The market tape

- **S&P 500 (SPX)**: -0.58%, closed at 7,673.52 - **Nasdaq Composite (COMP)**: -0.32%, closed at 26,421.41 - **Dow Jones Industrial Average (DJIA)**: -1.18%, closed at 52,786.07 - **Russell 2000 (RUT)**: -0.52%, closed at 2,960.2

Sector leaders and laggards

- Leaders: Energy +1.12%; Utilities +0.86%; Information Technology +0.32% - Laggards: Health Care -2.50%

Notable movers

Roivant Sciences Ltd. (ROIV) +18.75%

Roivant reported that the Phase 2 PHocus trial of mosliciguat met its primary endpoint and key secondary endpoints in pulmonary hypertension associated with interstitial lung disease. A major clinical-data repricing in a large, liquid biotechnology company, with volume roughly four times the prior session.

Sources: dated closing quote and market capitalization · primary company catalyst

Novartis AG (NVS) -13.93%

Novartis suffered multiple late-stage clinical setbacks, including pelacarsen missing its primary objective in a cardiovascular outcomes study and another failed rare-disease trial. The ADR posted one of its steepest declines on record and triggered broad read-through selling across large-cap biotechnology and medical-device stocks.

Sources: dated closing quote and volume · reported clinical catalyst · pelacarsen-failure corroboration

Solaris Energy Infrastructure, Inc. (SEI) +16.29%

Solaris raised its third- and fourth-quarter 2026 adjusted EBITDA guidance and initiated first-quarter 2027 guidance, citing stronger power-services contributions and acquired-business performance. The guidance midpoint increased 23% for the third quarter and 48% for the fourth quarter, providing a concrete earnings reset tied to power infrastructure.

Sources: dated closing quote and volume · primary company catalyst

Amgen Inc. (AMGN) -10.08%

Amgen fell on read-through from Novartis's failed pelacarsen cardiovascular trial, which raised concerns about Amgen's competing RNA-based Lp(a) treatment olpasiran. The decline was large enough to account for roughly 262 points of the Dow's 628-point loss and dominated health-care sector performance.

Sources: dated closing quote and volume · reported read-through catalyst · index-impact corroboration

Bloom Energy Corporation (BE) +9.63%

S&P Dow Jones Indices announced that Bloom Energy would enter the S&P 500 before trading opened on September 21, 2026. Index inclusion extended a powerful AI-power and distributed-generation rally, with more than $7.5 billion of session turnover.

Sources: dated closing quote and volume · primary index-announcement catalyst

Intel Corporation (INTC) +9.05%

Intel rallied after reporting indicated that the company could raise computer-chip prices the following month, reinforcing expectations for improving pricing power. A roughly 9% move in a mega-cap semiconductor generated more than $14 billion of turnover and helped offset weakness elsewhere in the major indexes.

Sources: dated closing quote and volume · reported catalyst

Stryker Corporation (SYK) -8.81%

Stryker sold off after its CFO discussed ongoing supply-chain challenges at the Wells Fargo Healthcare Conference. The warning sent a large medical-device company to a 52-week low and amplified an unusually broad health-care selloff.

Sources: dated closing quote and volume · market capitalization · reported conference catalyst

Boston Scientific Corporation (BSX) -5.90%

Boston Scientific said fallout from a cybersecurity incident disrupted product shipments and was expected to cause the company to miss its annual sales-growth and earnings estimates. The operational cyber event translated directly into a financial-guidance problem at a major medical-device supplier, with approximately $1.3 billion traded.

Sources: dated closing quote and volume · reported cybersecurity and guidance catalyst

Stock spotlight

No mover met the source-confidence threshold for a detailed spotlight.

_MacroShed Markets is informational analysis, not investment advice._